Dr. Anju Vasudevan, MD

Dr. Vasudevan practices at Florida Cancer Affiliates Ocala, Tampa Bay, North Florida in Ocala, Florida.

Dr. Vasudevan's NPI, 1043203888, was assigned on August 26, 2005. Dr. Vasudevan graduated from Lady Hardinge Medical College in 1980. Dr. Vasudevan holds Florida license ME52275.

Dr. Vasudevan's primary practice is Florida Cancer Affiliates Ocala, Tampa Bay, North Florida, at 3130 Sw 32nd Ave, Ocala, FL 34474-4445. The practice phone is (352) 732-4032.

Dr. Vasudevan's primary practice is Florida Cancer Affiliates Ocala, Tampa Bay, North Florida in Ocala, Florida. Dr. Vasudevan is also affiliated with HCA Florida Ocala Hospital. The medical group on file is Florida Cancer Affiliates. Dmand AI also links Dr. Vasudevan to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vasudevan practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Vasudevan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Vasudevan is board certified in internal medicine by the American Board of Internal Medicine. Dr. Vasudevan is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances, immune deficiency disease and lung cancer among the conditions Dr. Vasudevan treats.

CMS data shows 228,275 Medicare services from Dr. Vasudevan across 76 procedure codes in 2024, for 1,119 Medicare patients. Medicare paid $2,658,399 for them.

CMS counts 1,119 Medicare patients who saw Dr. Vasudevan in 2024. The largest group is 75 to 84, with 480 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vasudevan's median patient age at 74, with 64% women.

In 2024, Dr. Vasudevan wrote 2,384 Medicare Part D claims for 448 patients. 82% of them were for generic drugs. CMS names the drug for 2,078 of them, across 50 drugs with 11 or more claims each, at $3,971,009 in total drug cost. In 2023, CMS named 1,936 claims across 48 drugs.

Dr. Vasudevan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 25 papers to Dr. Vasudevan, published from 2006 to 2024. 2020 was the busiest year, with 4. The most frequent topics are Endothelial Cells, GABAergic Neurons and gamma-Aminobutyric Acid. Dr. Vasudevan has published most often in Sci Rep. Dr. Vasudevan's most frequent co-authors are Rakesh K. Jain, MD, Stefan G. Tullius, MD, PhD and Christiane J. Ferran, MD.

Dmand AI links Dr. Vasudevan to 5 clinical trials. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Vasudevan that name 1 trial.

CMS Open Payments shows 1,803 general payments to Dr. Vasudevan from 97 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 49% of the total. AstraZeneca Pharmaceuticals LP paid the most, $11,224. It also lists 3 research payments totaling $2,065 from 2019 to 2020, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Vasudevan, most recently CMS Stage 1 EHR in 2013.

Dr. Vasudevan graduated from Lady Hardinge Medical College in 1980.

Dr. Vasudevan is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.